The outcomes of the Checkmate 142 study in mCRC

Atrayee Basu Mallick, MD, shares her thoughts on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at Annual Meeting 2018.